Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more
Assertio Therapeutics Inc (ASRT) - Net Assets
Latest net assets as of September 2025: $105.80 Million USD
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has net assets worth $105.80 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($319.77 Million) and total liabilities ($213.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $105.80 Million |
| % of Total Assets | 33.09% |
| Annual Growth Rate | N/A |
| 5-Year Change | 118.11% |
| 10-Year Change | -61.57% |
| Growth Volatility | 143.2 |
Assertio Therapeutics Inc - Net Assets Trend (1996–2024)
This chart illustrates how Assertio Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Assertio Therapeutics Inc (1996–2024)
The table below shows the annual net assets of Assertio Therapeutics Inc from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $121.08 Million | -12.26% |
| 2023-12-31 | $138.00 Million | -38.86% |
| 2022-12-31 | $225.72 Million | +120.40% |
| 2021-12-31 | $102.41 Million | +84.48% |
| 2020-12-31 | $55.51 Million | -4.22% |
| 2019-12-31 | $57.96 Million | -73.70% |
| 2018-12-31 | $220.34 Million | +29.99% |
| 2017-12-31 | $169.51 Million | -32.41% |
| 2016-12-31 | $250.79 Million | -20.40% |
| 2015-12-31 | $315.06 Million | -13.55% |
| 2014-12-31 | $364.45 Million | +165.21% |
| 2013-12-31 | $137.42 Million | +63.72% |
| 2012-12-31 | $83.94 Million | -20.75% |
| 2011-12-31 | $105.92 Million | +358.40% |
| 2010-12-31 | $23.11 Million | +46.93% |
| 2009-12-31 | $15.73 Million | -52.57% |
| 2008-12-31 | $33.15 Million | -27.17% |
| 2007-12-31 | $45.52 Million | +266.81% |
| 2006-12-31 | $-27.29 Million | -503.62% |
| 2005-12-31 | $6.76 Million | -19.54% |
| 2004-12-31 | $8.40 Million | -75.70% |
| 2003-12-31 | $34.58 Million | +639.08% |
| 2002-12-31 | $-6.41 Million | -334.19% |
| 2001-12-31 | $-1.48 Million | -132.21% |
| 2000-12-31 | $4.59 Million | -50.25% |
| 1999-12-31 | $9.22 Million | +0.20% |
| 1998-12-31 | $9.20 Million | +124.39% |
| 1997-12-31 | $4.10 Million | +1125.00% |
| 1996-12-31 | $-400.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Assertio Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 67202400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.01% |
| Other Components | $794.20 Million | 655.92% |
| Total Equity | $121.08 Million | 100.00% |
Assertio Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Assertio Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Frequency Therapeutics Inc
NASDAQ:KRRO
|
$71.41 Million |
|
Kwan's International Co., Ltd.
TWO:6101
|
$71.43 Million |
|
Patec Precision Industry Co Ltd
TW:2236
|
$71.43 Million |
|
Hf Foods Group Inc
NASDAQ:HFFG
|
$71.43 Million |
|
YEAH1 Group Corp
VN:YEG
|
$71.34 Million |
|
Xaar plc
PINK:XAARF
|
$71.32 Million |
|
Bioceltix S.A.
WAR:BCX
|
$71.31 Million |
|
Honghua Group Limited
F:4HB
|
$71.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Assertio Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 138,003,000 to 121,081,000, a change of -16,922,000 (-12.3%).
- Net loss of 21,581,000 reduced equity.
- Share repurchases of 350,000 reduced equity.
- Other factors increased equity by 5,009,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.58 Million | -17.82% |
| Share Repurchases | $350.00K | -0.29% |
| Other Changes | $5.01 Million | +4.14% |
| Total Change | $- | -12.26% |
Book Value vs Market Value Analysis
This analysis compares Assertio Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.66x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $-5.76 | $12.50 | x |
| 1997-12-31 | $55.35 | $12.50 | x |
| 1998-12-31 | $87.37 | $12.50 | x |
| 1999-12-31 | $85.43 | $12.50 | x |
| 2000-12-31 | $37.54 | $12.50 | x |
| 2001-12-31 | $-8.67 | $12.50 | x |
| 2002-12-31 | $-26.28 | $12.50 | x |
| 2003-12-31 | $84.82 | $12.50 | x |
| 2004-12-31 | $14.56 | $12.50 | x |
| 2005-12-31 | $10.19 | $12.50 | x |
| 2006-12-31 | $-39.44 | $12.50 | x |
| 2007-12-31 | $58.92 | $12.50 | x |
| 2008-12-31 | $40.78 | $12.50 | x |
| 2009-12-31 | $18.31 | $12.50 | x |
| 2010-12-31 | $25.98 | $12.50 | x |
| 2011-12-31 | $113.30 | $12.50 | x |
| 2012-12-31 | $90.10 | $12.50 | x |
| 2013-12-31 | $143.28 | $12.50 | x |
| 2014-12-31 | $21.99 | $12.50 | x |
| 2015-12-31 | $20.96 | $12.50 | x |
| 2016-12-31 | $16.37 | $12.50 | x |
| 2017-12-31 | $162.20 | $12.50 | x |
| 2018-12-31 | $205.89 | $12.50 | x |
| 2019-12-31 | $49.18 | $12.50 | x |
| 2020-12-31 | $31.77 | $12.50 | x |
| 2021-12-31 | $35.59 | $12.50 | x |
| 2022-12-31 | $61.93 | $12.50 | x |
| 2023-12-31 | $29.14 | $12.50 | x |
| 2024-12-31 | $19.06 | $12.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Assertio Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.27%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.35x
- Recent ROE (-17.82%) is above the historical average (-66.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 0.00% | -166.67% | 1.00x | 0.00x | $-460.00K |
| 1997 | -29.27% | -200.00% | 0.13x | 1.12x | $-1.61 Million |
| 1998 | -30.43% | -350.00% | 0.08x | 1.12x | $-3.72 Million |
| 1999 | -186.68% | -14921.74% | 0.01x | 2.43x | $-18.13 Million |
| 2000 | -211.57% | -546.27% | 0.20x | 1.90x | $-10.16 Million |
| 2001 | 0.00% | -479.13% | 0.42x | 0.00x | $-17.45 Million |
| 2002 | 0.00% | -812.35% | 0.07x | 0.00x | $-12.85 Million |
| 2003 | -86.81% | -3056.56% | 0.02x | 1.38x | $-33.47 Million |
| 2004 | -319.80% | -13266.41% | 0.01x | 2.72x | $-27.71 Million |
| 2005 | -361.89% | -555.40% | 0.07x | 9.82x | $-25.14 Million |
| 2006 | 0.00% | -415.23% | 0.18x | 0.00x | $-36.93 Million |
| 2007 | 108.13% | 75.05% | 0.81x | 1.77x | $44.67 Million |
| 2008 | -46.16% | -43.92% | 0.37x | 2.87x | $-18.62 Million |
| 2009 | -139.95% | -38.12% | 0.63x | 5.82x | $-23.58 Million |
| 2010 | 16.86% | 4.82% | 0.93x | 3.77x | $1.59 Million |
| 2011 | 66.77% | 53.19% | 0.81x | 1.55x | $60.13 Million |
| 2012 | -35.48% | -32.79% | 0.64x | 1.69x | $-38.17 Million |
| 2013 | 31.52% | 32.27% | 0.26x | 3.70x | $29.57 Million |
| 2014 | 36.15% | 33.75% | 0.55x | 1.95x | $95.32 Million |
| 2015 | -24.04% | -22.10% | 0.25x | 4.33x | $-107.24 Million |
| 2016 | -35.38% | -19.46% | 0.37x | 4.89x | $-113.80 Million |
| 2017 | -60.47% | -26.92% | 0.37x | 6.13x | $-119.45 Million |
| 2018 | 16.75% | 11.84% | 0.33x | 4.23x | $14.87 Million |
| 2019 | -374.76% | -94.63% | 0.44x | 9.10x | $-223.00 Million |
| 2020 | -50.70% | -26.04% | 0.36x | 5.46x | $-33.70 Million |
| 2021 | -1.25% | -1.15% | 0.34x | 3.19x | $-11.52 Million |
| 2022 | 48.57% | 70.17% | 0.38x | 1.83x | $87.05 Million |
| 2023 | -240.53% | -218.28% | 0.53x | 2.08x | $-345.74 Million |
| 2024 | -17.82% | -17.27% | 0.44x | 2.35x | $-33.69 Million |
Industry Comparison
This section compares Assertio Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Assertio Therapeutics Inc (ASRT) | $105.80 Million | 0.00% | 2.02x | $71.37 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |